'Gilead Will Pay Privately Held Ouro's Investors Roughly $1.5B Upfront In Cash And At Least Extra $500M If Certain Clinical Trial Milestones Are Hit; Talks Between Gilead And Ouro Medicines Are At An Advanced Stage And A Deal Could Be Announced In The Coming Days' - Financial Times